论文部分内容阅读
目的分析不同方案治疗支气管哮喘的临床疗效,探寻合适的治疗方案。方法收集我院内科收治的支气管哮喘患者共60例,按随机法分为A组和B组,每组各30例。A组给予患者新型糖皮质激素氟替卡松,B组给予患者氟替卡松与β2受体激动剂沙美特罗,治疗完成后评价两组患者的体征消失时间、症状缓解时间、疗效及复发情况等,并进行统计学分析比较。结果 A组患者在临床症状缓解时间明显较短、肺部体征消失时间与B组比较明显不同,差异均具有统计学意义(P<0.05);同时,两组患者在治疗后治疗有效率、复发率也均不同,差异有统计学意义(P<0.05)。结论在支气管哮喘患者中应用糖皮质激素与β2受体激动剂联合的治疗方案较单用药方案,其临床疗效更为显著,复发率低,恢复时间短,值得应用推广。
Objective To analyze the clinical effects of different regimens in the treatment of bronchial asthma and explore the appropriate treatment plan. Methods Sixty patients with bronchial asthma admitted to our hospital were randomly divided into A group and B group, with 30 cases in each group. Patients in group A were given fluticasone, a new glucocorticoid, and in group B, fluticasone and beta 2 agonist salmeterol were administered to patients in group B. The disappearance time, symptom relief time, curative effect and recurrence of the two groups were evaluated after treatment and statistically Analysis and comparison. Results A group of patients in clinical symptoms were significantly shorter remission time, the disappearance of lung signs compared with the B group were significantly different, the differences were statistically significant (P <0.05); the same time, the two groups of patients after treatment, the effective rate of relapse Rates are also different, the difference was statistically significant (P <0.05). Conclusion The combination of glucocorticoid and β2 agonist in patients with bronchial asthma is more effective than single-agent in the treatment of bronchial asthma. The clinical efficacy is more significant, the recurrence rate is low and the recovery time is short, which is worthy of popularization.